Search results for "Cancers"

showing 10 items of 276 documents

Single-Nucleotide Polymorphism Array-Based Karyotyping of Acute Promyelocytic Leukemia

2014

Acute promyelocytic leukemia (APL) is characterized by the t(15;17)(q22;q21), but additional chromosomal abnormalities (ACA) and other rearrangements can contribute in the development of the whole leukemic phenotype. We hypothesized that some ACA not detected by conventional techniques may be informative of the onset of APL. We performed the high-resolution SNP array (SNP-A) 6.0 (Affymetrix) in 48 patients diagnosed with APL on matched diagnosis and remission sample. Forty-six abnormalities were found as an acquired event in 23 patients (48%): 22 duplications, 23 deletions and 1 Copy-Neutral Loss of Heterozygocity (CN-LOH), being a duplication of 8(q24) (23%) and a deletion of 7(q33-qter) (…

AdultMaleAcute promyelocytic leukemiamedicine.medical_specialtyAdolescentOncogene Proteins FusionMicroarrayslcsh:MedicineLoss of HeterozygosityChromosomal translocationBiologyResearch and Analysis MethodsPolymorphism Single NucleotideTranslocation GeneticHematologic Cancers and Related DisordersLoss of heterozygosityYoung AdultLeukemia Promyelocytic AcuteLeukemiasGene duplicationMedicine and Health SciencesmedicineHumanslcsh:ScienceAgedChromosome AberrationsChromosomes Human Pair 15Multidisciplinarylcsh:RBreakpointCytogeneticsBiology and Life SciencesComputational BiologyHematologyMiddle AgedPrognosismedicine.diseaseMolecular biologyLeukemiaBioassays and Physiological AnalysisKaryotypingCancer researchlcsh:QFemaleResearch ArticleChromosomes Human Pair 17SNP arrayPLoS ONE
researchProduct

A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus

2014

Contains fulltext : 137763.pdf (Publisher’s version ) (Open Access) Recent genome-wide association studies (GWAS) of Hodgkin lymphoma (HL) have identified associations with genetic variation at both HLA and non-HLA loci; however, much of heritable HL susceptibility remains unexplained. Here we perform a meta-analysis of three HL GWAS totaling 1,816 cases and 7,877 controls followed by replication in an independent set of 1,281 cases and 3,218 controls to find novel risk loci. We identify a novel variant at 19p13.3 associated with HL (rs1860661; odds ratio (OR)=0.81, 95% confidence interval (95% CI)=0.76-0.86, Pcombined=3.5 x 10(-10)), located in intron 2 of TCF3 (also known as E2A), a regul…

AdultMaleAdolescent[SDV]Life Sciences [q-bio]TRANSCRIPTION FACTOR E2AGENETIC-ASSOCIATIONGeneral Physics and AstronomyLocus (genetics)Genome-wide association studyHuman leukocyte antigenBiologyGeneral Biochemistry Genetics and Molecular BiologyArticleDISEASEYoung AdultBasic Helix-Loop-Helix Transcription FactorsHumansTOOLGenetic Predisposition to DiseaseAlleleGENOME-WIDE ASSOCIATIONEPSTEIN-BARR-VIRUSGenetic associationAgedGeneticsAged 80 and overRISKMultidisciplinaryCELL-TYPECase-control studyGenetic VariationGeneral ChemistryOdds ratioGenomicsMiddle AgedALLELESHodgkin DiseaseCANCERMalaltia de HodgkinHodgkin lymphoma (HL)GenòmicaGenetic epidemiologyCase-Control StudiesUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]Hodgkin's diseaseChromosomes Human Pair 19Genome-Wide Association Study
researchProduct

Population attributable risk of tobacco and alcohol for upper aerodigestive tract cancer.

2011

Tobacco and alcohol are major risk factors for upper aerodigestive tract (UADT) cancer and significant variation is observed in UADT cancer rates across Europe. We have estimated the proportion of UADT cancer burden explained by tobacco and alcohol and how this varies with the incidence rates across Europe, cancer sub-site, gender and age. This should help estimate the minimum residual burden of other risk factors to UADT cancer, including human papillomavirus. We analysed 1981 UADT cancer cases and 1993 controls from the ARCAGE multicentre study. We estimated the population attributable risk (PAR) of tobacco alone, alcohol alone and their joint effect. Tobacco and alcohol together explaine…

AdultMaleCancer Researchmedicine.medical_specialtyAlcohol DrinkingEsophageal NeoplasmsAlcoholchemistry.chemical_compoundRisk FactorsTobaccomedicineHumansPopulation attributable riskGynecologyMouth neoplasmbusiness.industryIncidenceMedicine (all)Incidence (epidemiology)SmokingCase-control studyCancerAlcohol; ARCAGE study; Population attributable risk; Tobacco; Upper aerodigestive tract cancer; Adult; Alcohol Drinking; Case-Control Studies; Esophageal Neoplasms; Europe; Female; Humans; Incidence; Male; Middle Aged; Mouth Neoplasms; Otorhinolaryngologic Neoplasms; Risk Factors; Smoking; Oral Surgery; Medicine (all); Oncology; Cancer ResearchMiddle Agedmedicine.diseaseUpper aerodigestive tract cancerARCAGE studyEuropeOtorhinolaryngologic NeoplasmsUpper aerodigestive tractOncologychemistryCase-Control StudiesAttributable riskFemaleMouth NeoplasmsUpper aerodigestive tract cancer; ARCAGE study; Population attributable risk; Tobacco; AlcoholOral SurgeryAlcoholbusinessOropharyngeal CancersDemography
researchProduct

The EORTC module for quality of life in patients with thyroid cancer: phase III

2017

The purpose of the study was to pilot-test a questionnaire measuring health-related quality of life (QoL) in thyroid cancer patients to be used with the European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire EORTC QLQ-C30. A provisional questionnaire with 47 items was administered to patients treated for thyroid cancer within the last 2 years. Patients were interviewed about time and help needed to complete the questionnaire, and whether they found the items understandable, confusing or annoying. Items were kept in the questionnaire if they fulfilled pre-defined criteria: relevant to the patients, easy to understand, not confusing, few missing values, neither …

AdultMaleCancer Researchmedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismPilot ProjectsIodine Radioisotopes03 medical and health sciences0302 clinical medicineEndocrinologyQuality of lifeInternal medicineSurveys and QuestionnairesMedicineHumansIn patientThyroid NeoplasmsThyroid cancerProtein Kinase InhibitorsAgedAged 80 and overbusiness.industryCancerMiddle Agedmedicine.diseasehumanitiesSurgeryOncology030220 oncology & carcinogenesisQuality of LifeFemalebusinessRare cancers Radboud Institute for Health Sciences [Radboudumc 9]
researchProduct

Survival of Adults with Acute Lymphoblastic Leukemia in Germany and the United States

2014

BackgroundAdulthood acute lymphoblastic leukemia (ALL) is a rare disease. In contrast to childhood ALL, survival for adults with ALL is poor. Recently, new protocols, including use of pediatric protocols in young adults, have improved survival in clinical trials. Here, we examine population level survival in Germany and the United States (US) to gain insight into the extent to which changes in clinical trials have translated into better survival on the population level.MethodsData were extracted from the Surveillance, Epidemiology, and End Results database in the US and 11 cancer registries in Germany. Patients age 15-69 diagnosed with ALL were included. Period analysis was used to estimate…

AdultMalePediatricsmedicine.medical_specialtyAdolescentNon-Clinical MedicineEpidemiologyScienceLymphoblastic LeukemiaBiostatisticsHematologic Cancers and Related DisordersGermanyLeukemiasEpidemiologyHumansMedicineStatistical MethodsYoung adultSurvival analysisAgedHealth Care PolicyMultidisciplinaryRelative survivalbusiness.industryStatisticsQRCancers and NeoplasmsCancerHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaAcute Lymphoblastic Leukemiamedicine.diseaseSurvival AnalysisUnited StatesClinical trialOncologyUnited States ; age groups ; cancer treatment ; German people ; Germany ; cancer detection and diagnosis ; acute lymphoblastic leukemia ; leukemiasMedicineFemaleHealth StatisticsbusinessMathematicsResearch ArticleRare diseasePLoS ONE
researchProduct

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer

2015

Abstract Tumor growth in the context of EGFR inhibitor resistance may remain EGFR-dependent and is mediated by mechanisms including compensatory ligand upregulation and de novo gene alterations. Sym004 is a two-antibody mixture targeting nonoverlapping EGFR epitopes. In preclinical models, Sym004 causes significant EGFR internalization and degradation, which translates into superior growth inhibition in the presence of ligands. In this phase I trial, we observed grade 3 skin toxicity and hypomagnesemia as mechanism-based dose-limiting events during dose escalation. In dose-expansion cohorts of 9 and 12 mg/kg of Sym004 weekly, patients with metastatic colorectal cancer and acquired EGFR inhi…

AdultMaleProto-Oncogene Proteins B-rafClass I Phosphatidylinositol 3-KinasesColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Antineoplastic AgentsContext (language use)Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]LigandsPhosphatidylinositol 3-Kinaseschemistry.chemical_compoundCell Line TumorHumansMedicinePanitumumabNeoplasm MetastasisAgedEGFR inhibitorsAged 80 and overDose-Response Relationship DrugCetuximabbusiness.industryGene AmplificationAntibodies MonoclonalCancerMiddle Agedmedicine.diseaseErbB ReceptorsClinical trialGenes rasTreatment OutcomeOncologychemistryMutationImmunologyCancer researchFemaleGrowth inhibitionColorectal Neoplasmsbusinessmedicine.drug
researchProduct

Magnetic Resonance Microscopy at 14 Tesla and Correlative Histopathology of Human Brain Tumor Tissue

2011

Magnetic Resonance Microscopy (MRM) can provide high microstructural detail in excised human lesions. Previous MRM images on some experimental models and a few human samples suggest the large potential of the technique. The aim of this study was the characterization of specific morphological features of human brain tumor samples by MRM and correlative histopathology. We performed MRM imaging and correlative histopathology in 19 meningioma and 11 glioma human brain tumor samples obtained at surgery. To our knowledge, this is the first MRM direct structural characterization of human brain tumor samples. MRM of brain tumor tissue provided images with 35 to 40 µm spatial resolution. The use of …

AdultMalemedicine.medical_specialtyPathologyPsammoma bodyBrain tumorlcsh:MedicineDiagnostic RadiologyMeningiomaDiagnostic MedicineGliomaBiopsyPathologymedicineHumanslcsh:ScienceNeurological TumorsNeuropathologyAgedAged 80 and overMultidisciplinaryintegumentary systemmedicine.diagnostic_testBrain Neoplasmsbusiness.industryMagnetic resonance microscopylcsh:RCancers and NeoplasmsCalcinosisMagnetic resonance imagingMiddle Agedmedicine.diseaseMagnetic Resonance ImagingSurgical OncologyOncologyAnatomical PathologyMedicinelcsh:QSurgeryFemaleHistopathologyCollagenRadiologybusinessResearch ArticlePLoS ONE
researchProduct

Synthesis and evaluation of zirconium-89 labelled and long-lived GLP-1 receptor agonists for PET imaging

2020

Contains fulltext : 220838.pdf (Publisher’s version ) (Open Access) INTRODUCTION: Lately, zirconium-89 has shown great promise as a radionuclide for PET applications of long circulating biomolecules. Here, the design and synthesis of protracted and long-lived GLP-1 receptor agonists conjugated to desferrioxamine and labelled with zirconium-89 is presented with the purpose of studying their in vivo distribution by PET imaging. The labelled conjugates were evaluated and compared to a non-labelled GLP-1 receptor agonist in both in vitro and in vivo assays to certify that the modification did not significantly alter the peptides' structure or function. Finally, the zirconium-89 labelled peptide…

AgonistCancer ResearchBiodistributionmedicine.drug_class[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/ImagingPeptide[CHIM.THER]Chemical Sciences/Medicinal Chemistry[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineChemistry Techniques SyntheticPharmacologyRare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]Glucagon-Like Peptide-1 Receptor030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineIn vivomedicineRadiology Nuclear Medicine and imagingTissue DistributionAmino Acid SequenceReceptorGlucagon-like peptide 1 receptorchemistry.chemical_classificationRadioisotopesRadiochemistryChemistryIn vitro toxicology030220 oncology & carcinogenesisDrug DesignIsotope LabelingPositron-Emission Tomography[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyMolecular MedicineZirconiumPeptidesNanomedicine Radboud Institute for Molecular Life Sciences [Radboudumc 19]Ex vivoHalf-Life
researchProduct

Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients

2011

Background\ud Receptor activator of NFkB (RANK), its ligand (RANKL) and the decoy receptor of RANKL (osteoprotegerin, OPG) play a pivotal role in bone remodeling by regulating osteoclasts formation and activity. RANKL stimulates migration of RANK-expressing tumor cells in vitro, conversely inhibited by OPG.\ud \ud Materials and Methods\ud We examined mRNA expression levels of RANKL/RANK/OPG in a publicly available microarray dataset of 295 primary breast cancer patients. We next analyzed RANK expression by immunohistochemistry in an independent series of 93 primary breast cancer specimens and investigated a possible association with clinicopathological parameters, bone recurrence and surviv…

Anatomy and PhysiologyMicroarraysSettore MED/06 - Oncologia MedicaCancer TreatmentLigandsMetastasisBone remodelingMetastasisBasic Cancer ResearchBreast TumorsBone and Soft Tissue SarcomasNeoplasm MetastasisMusculoskeletal SystemOligonucleotide Array Sequence AnalysisMultidisciplinaryPredictive markerReceptor Activator of Nuclear Factor-kappa BQRBone metastasisMiddle AgedImmunohistochemistryGene Expression Regulation NeoplasticOncologyRANKLMedicineFemaleResearch Articlemusculoskeletal diseasesmedicine.medical_specialtyHistologyScienceBone NeoplasmsBreast NeoplasmsBiologyBreast cancerAntibody TherapySDG 3 - Good Health and Well-beingOsteoprotegerinInternal medicinemedicineHumansRNA MessengerBoneBiologyAgedBreast cancer bone metastasis RANK-RANKLRANK LigandOsteoprotegerinComputational BiologyCancers and NeoplasmsRANK Ligandmedicine.diseaseEndocrinologyCancer researchbiology.protein
researchProduct

Antibody Complementarity-Determining Regions (CDRs) Can Display Differential Antimicrobial, Antiviral and Antitumor Activities

2008

9 p. Background: Complementarity-determining regions (CDRs) are immunoglobulin (Ig) hypervariable domains that determine specific antibody (Ab) binding. We have shown that synthetic CDR-related peptides and many decapeptides spanning the variable region of a recombinant yeast killer toxin-like antiidiotypic Ab are candidacidal in vitro. An alanine-substituted decapeptide from the variable region of this Ab displayed increased cytotoxicity in vitro and/or therapeutic effects in vivo against various bacteria, fungi, protozoa and viruses. The possibility that isolated CDRs, represented by short synthetic peptides, may display antimicrobial, antiviral and antitumor activities irrespective of Ab…

Antifungal AgentsBIOCHEMISTRY AND MOLECULAR BIOLOGYMolecular Sequence DataImmunologylcsh:MedicineAntineoplastic AgentsMicrobial Sensitivity TestsComplementarity determining regionBiologyAntiviral AgentsOncology/Skin CancersAntibodiesMiceMicrobiology/Applied MicrobiologyAntigenBiochemistry/Protein ChemistryInfectious Diseases/Fungal InfectionsIn vivoCell Line TumorCandida albicansInfectious Diseases/Viral InfectionsAnimalsHumansAmino Acid Sequencelcsh:SciencePeptide sequenceMultidisciplinaryMEDICINElcsh:RAntimicrobialComplementarity Determining RegionsVirologyIn vitroOncologyBiochemistryViral replicationAGRICULTURAL AND BIOLOGICAL SCIENCESVirology/Immunodeficiency VirusesHIV-1biology.proteinlcsh:QAntibodyResearch ArticlePLoS ONE
researchProduct